EGFR Gene Copy Number as a Prognostic Marker in Colorectal Cancer Patients Treated with Cetuximab or Panitumumab: A Systematic Review and Meta Analysis

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Jiang, Zheng ^a,b   Li, Chunxiang ^a   Li, Fuyuan ^a   Wang, Xishan ^a,b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Biopharmaceutical Institute of the Heilongjiang Academy of Medical Sciences   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; PANITUMUMAB;

ADVANCED CANCER; ARTICLE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; DRUG EFFECT; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; METASTASIS; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SYSTEMATIC REVIEW;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; GENE DOSAGE; HUMANS; PROGNOSIS; PUBLICATION BIAS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84874167463     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056205     Document Type: Article

References (38)

1. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, et al. (2010) Colorectal cancer. Lancet 375: 1030-1047.
2. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, et al. (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040-8.
3. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-45.
4. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, et al. (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658-64.
5. Schrag D, (2004) The price tag on progress: Chemotherapy for colorectal cancer. N Engl J Med 351: 317-319.
6. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, et al. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-5.
7. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, et al. (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25: 3230-7.
8. Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, et al. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374-9.
9. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, et al. (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6: 279-86.
10. Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, et al. (2007) Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 25: 3238-45.
11. Personeni N, Fieuws S, Piessevaux H, De Hertogh G, De Schutter J, et al. (2008) Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res 14: 5869-76.
12. Cappuzzo F, Finocchiaro G, Rossi E, Jänne PA, Carnaghi C, et al. (2008) EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 19: 717-23.
13. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR, (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16.
14. Parmar MK, Torri V, Stewart L, (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834.
15. Kyrgiou M, Salanti G, Pavlidis N, Paraskevaidis E, Ioannidis JP, (2006) Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst 98: 1655-1663.
16. Williamson PR, Smith CT, Hutton JL, Marson AG, (2002) Aggregate data meta-analysis with time-to-event outcome. Stat Med 21: 3337-51.
17. Lau J, Ioannidis JP, Schmid CH, (1997) Quantitative synthesis in systematicreviews. Ann Intern Med 127: 820-826.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
19. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
20. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
21. Gonçalves A, Esteyries S, Taylor-Smedra B, Lagarde A, Ayadi M, et al. (2008) A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMC Cancer 8: 169.
22. Scartozzi M, Bearzi I, Mandolesi A, Pierantoni C, Loupakis F, et al. (2009) Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. BMC Cancer 9: 303.
23. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, et al. (2009) Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27: 5924-5930.
24. Li YH, Wang F, Shen L, Deng YM, Shao Q, et al. (2011) EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients. Clin Cancer Res 17: 382-90.
25. Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, et al. (2010) Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 46: 1997-2009.
26. Campanella C, Mottolese M, Cianciulli A, Torsello A, Merola R, et al. (2010) Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab. J Transl Med 8: 36.
27. Bengala C, Bettelli S, Bertolini F, Sartori G, Fontana A, et al. (2010) Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. Br J Cancer 103: 1019-24.
28. Scartozzi M, Giampieri R, Maccaroni E, Mandolesi A, Giustini L, et al. (2012) Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. Ann Oncol 23: 1706-12.
29. Lin JK, Lin AJ, Lin CC, Lan YT, Yang SH, et al. (2011) The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy. J Surg Oncol 104: 661-666.
30. Ålgars A, Lintunen M, Carpén O, Ristamäki R, Sundström J, (2011) EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer. Br J Cancer 105: 255-262.
31. Dahabreh IJ, Linardou H, Kosmidis P, Bafaloukos D, Murray S, (2011) EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer. Ann Oncol 22: 545-552.
32. Yang ZY, Shen WX, Hu XF, Zheng DY, Wu XY, et al. (2012) EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis. J Hematol Oncol 5: 52.
33. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, et al. (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658-1664.
34. Van Cutsem E, Siena S, Humblet Y, Canon JL, Maurel J, et al. (2008) An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 19: 92-98.
35. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, et al. (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23: 1803-1810.
36. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, et al. (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21: 3798-807.
37. Martin V, Mazzucchelli L, Frattini M, (2009) An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology. J Clin Pathol 62: 314-324.
38. Sartore-Bianchi A, Fieuws S, Veronese S, Moroni M, Personeni N, et al. (2012) Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study. J Clin Pathol. 65: 218-23.